In subgroup analysis of glioblastoma, IDH-wildtype according to WHO CNS tumor classification 2021, PFS was significantly longer (median, 514 days (95% CI, 438–676 days) vs. median, 328 days (95% CI, 285–387 days)) in the methylated group than in the unmethylated group (p = 0.0001) (Supplementary Figure S2), and patients with methylated MGMT showed a HR of 0.51 (95% CI, 0.36–0.72). The gene discussed is MGMT; the disease is glioblastoma.